Base-case results and NMBs for bevacizumab plus SOC vs SOC alone, from a US health system and societal perspective
| Strategy . | Cost . | Incremental cost . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | NMB . | iNMB (95% credible interval) . |
|---|---|---|---|---|---|---|
| Base-case model (health system perspective) | ||||||
| Bevacizumab | $428 000 | — | 9.3 | 1.0 | $973 000 | $433 000 (215 000-942 000) |
| SOC | $699 000 | $271 000 | 8.3 | — | $540 000 | |
| Base-case model (societal perspective) | ||||||
| Bevacizumab | $435 000 | — | 9.3 | 1.0 | $967 000 | $444 000 (217 000-973 000) |
| SOC | $717 000 | $281 000 | 8.3 | — | $523 000 | |
| Strategy . | Cost . | Incremental cost . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | NMB . | iNMB (95% credible interval) . |
|---|---|---|---|---|---|---|
| Base-case model (health system perspective) | ||||||
| Bevacizumab | $428 000 | — | 9.3 | 1.0 | $973 000 | $433 000 (215 000-942 000) |
| SOC | $699 000 | $271 000 | 8.3 | — | $540 000 | |
| Base-case model (societal perspective) | ||||||
| Bevacizumab | $435 000 | — | 9.3 | 1.0 | $967 000 | $444 000 (217 000-973 000) |
| SOC | $717 000 | $281 000 | 8.3 | — | $523 000 | |
Bevacizumab is a cost-saving treatment strategy that accrues NMB.